Drugs / MZE829
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06830629 | Feb 2025 → Sep 2026 overdue | proteinuria | Maze Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-03-25 | Maze Therapeutics | Results Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights mazetx.com ↗
today’s positive topline data from our Phase 2 HORIZON trial of MZE829 in broad AMKD |
| 2026-03-25 | Maze Therapeutics | Results Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease mazetx.com ↗
The results demonstrated that treatment with MZE829 led to a clinically meaningful mean reduction in proteinuria, as measured by urinary albumin-to-creatinine ratio (uACR), of 35.6% at week 12 in broad AMKD patients, with 50% of patients achieving a greater than 30% reduction in uACR. |
| 2024-10-25 | Maze Therapeutics | Results Maze Therapeutics Reports Positive First-in-Human Data from Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (AKD) mazetx.com ↗
Results demonstrated that MZE829 was well tolerated at single doses up to 480 mg and multiple doses up to 350 mg, with all treatment-related adverse events reported as mild and no severe or serious adverse events reported. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MZE829 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06830629 ↗ |
| Route | Oral | “Capsules for oral administration” NCT06830629 ↗ |